A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

(2011) D. van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis

(2011) David Ternant et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

(2011) X. Baraliakos et al.   RHEUMATOLOGY

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

(2011) Emilie Ducourau et al.   ARTHRITIS RESEARCH & THERAPY

Evaluating equivalence and noninferiority trials

(2010) A. Dasgupta et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study

(2009) Roman Krzysiek et al.   ARTHRITIS AND RHEUMATISM

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis

(2008) C Lukas et al.   ANNALS OF THE RHEUMATIC DISEASES